This is a demo store. No orders will be fulfilled.

Prexasertib dihydrochloride - 98%, high purity , CAS No.1234015-54-3

    Grade & Purity:
  • ≥98%
In stock
Item Number
P413719
Grouped product items
SKU Size
Availability
Price Qty
P413719-2mg
2mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$51.90
P413719-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$107.90
P413719-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$345.90
P413719-50mg
50mg
3
$543.90

Chk1 Selective Inhibitors

Basic Description

Synonyms LY2606368 diHCl | LY2606368 Prexasertib HCl | 9RFT476U2L | LY2606368 2HCl | EX-A758A | 2-Pyrazinecarbonitrile, 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]-, hydrochloride (1:2) | LY2606368 dihydrochloride | LY-2606368 dihydrochloride
Specifications & Purity ≥98%
Biochemical and Physiological Mechanisms Prexasertib (LY2606368) is an ATP-competitive CHK1 inhibitor with a Ki value of 0.9 nmol/L. For CHK2 and RSK, its IC50 values are 8 nM and 9 nM respectively in cell-free assay.
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

Information

Prexasertib (LY2606368) is an ATP-competitiveCHK1inhibitor with a Ki value of 0.9 nmol/L. For CHK2 and RSK, its IC50 values are 8 nM and 9 nM respectively in cell-free assay.


Targets

Chk1 (Cell-free assay); Chk2 (Cell-free assay); RSK (Cell-free assay) 0.9 nM(Ki); 8 nM; 9 nM


In vitro

In nonclinical studies, LY2606368 induced DNA damage as measured by replication catastrophe and increases in pH2A.X, a marker of double-stranded DNA breaks. Treatment of cells with LY2606368 results in the rapid appearance of TUNEL and pH2AX-positive double-stranded DNA breaks in the S-phase cell population. In a functional assay, LY2606368 potently abrogated the G2–M checkpoint activated by doxorubicin in p53-deficient HeLa cells with an EC50 of 9 nmol/L. LY2606368 was broadly antiproliferative with IC50 values typically <50 nmol/L in the most sensitive cell lines with a minority of cell lines showing considerable resistance with IC50\'s >1,000 nmol/L. LY2606368 requires CDC25A and CDK2 to cause DNA damage.


In vivo

LY2606368 inhibited tumor growth in cancer xenografts as monotherapy and in combination with other agents. In an orthotopic SKOV3 ovarian cancer model, LY2606368 was shown to inhibit the growth of primary tumors and significantly reduce the incidence of metastases and ascites accumulation. LY2606368 also demonstrated efficacy in an SW1990 orthotopic pancreatic cancer model resulting in a 92% inhibition of primary tumor growth and the elimination of metastases to the lymphnode, spleen, and intestine.


Cell Research(from reference)

Cell lines:HeLa cells 

Concentrations:33 or 100 nmol/L 

Incubation Time:12 h 

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Organoheterocyclic compounds
Class Azoles
Subclass Pyrazoles
Intermediate Tree Nodes Not available
Direct Parent Phenylpyrazoles
Alternative Parents Phenoxy compounds  Methoxybenzenes  Anisoles  Aminopyrazines  Alkyl aryl ethers  Imidolactams  Heteroaromatic compounds  Secondary amines  Nitriles  Azacyclic compounds  Monoalkylamines  Hydrochlorides  Hydrocarbon derivatives  
Molecular Framework Aromatic heteromonocyclic compounds
Substituents Phenylpyrazole - Phenoxy compound - Anisole - Phenol ether - Methoxybenzene - Alkyl aryl ether - Aminopyrazine - Monocyclic benzene moiety - Pyrazine - Benzenoid - Imidolactam - Heteroaromatic compound - Secondary amine - Nitrile - Carbonitrile - Ether - Azacycle - Organic nitrogen compound - Organonitrogen compound - Organooxygen compound - Primary amine - Primary aliphatic amine - Hydrochloride - Hydrocarbon derivative - Cyanide - Organic oxygen compound - Amine - Aromatic heteromonocyclic compound
Description This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
External Descriptors Not available

Names and Identifiers

Pubchem Sid 504770720
Pubchem Sid Url https://pubchem.ncbi.nlm.nih.gov/substance/504770720
IUPAC Name 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;dihydrochloride
INCHI InChI=1S/C18H19N7O2.2ClH/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17;;/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25);2*1H
InChIKey KMEIPKXRCJTZBZ-UHFFFAOYSA-N
Smiles COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N.Cl.Cl
Isomeric SMILES COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N.Cl.Cl
PubChem CID 46700755
Molecular Weight 438.31

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

1 results found

Lot Number Certificate Type Date Item
I2205356 Certificate of Analysis Jun 20, 2024 P413719

Chemical and Physical Properties

Solubility Solubility (25°C) In vitro DMSO: 17 mg/mL (38.78 mM); Water: Insoluble; Ethanol: Insoluble;
Molecular Weight 438.300 g/mol
XLogP3
Hydrogen Bond Donor Count 5
Hydrogen Bond Acceptor Count 8
Rotatable Bond Count 8
Exact Mass 437.113 Da
Monoisotopic Mass 437.113 Da
Topological Polar Surface Area 135.000 Ų
Heavy Atom Count 29
Formal Charge 0
Complexity 499.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 0
Covalently-Bonded Unit Count 3

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.